Trulieve Cannabis Corp. (NYSE:TRLV – Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 809,950 shares, a growth of 174.1% from the June 15th total of 295,465 shares. Based on an average daily volume of 2,214,683 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.4% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on TRLV. Wall Street Zen downgraded Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Weiss Ratings initiated coverage on Trulieve Cannabis in a research note on Tuesday, June 16th. They issued a “sell (d-)” rating for the company. Finally, Zacks Research raised Trulieve Cannabis to a “hold” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Trulieve Cannabis currently has an average rating of “Reduce”.
Check Out Our Latest Stock Report on Trulieve Cannabis
Insider Transactions at Trulieve Cannabis
Trulieve Cannabis Price Performance
TRLV traded down $0.49 during trading on Wednesday, reaching $8.57. 715,446 shares of the company’s stock were exchanged, compared to its average volume of 630,215. Trulieve Cannabis has a 1 year low of $4.00 and a 1 year high of $13.28.
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.
Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.
Featured Stories
- Five stocks we like better than Trulieve Cannabis
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
